Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: Protocol for randomised controlled home trial to evaluate the Suspend before low function

H.C. Roby, J. Fairchild, B.R. King, G.R. Ambler, F. Cameron, Elizabeth A. Davis, Timothy W. Jones

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Introduction: Innovations with sensor-augmented pump therapy (SAPT) to reduce hypoglycaemia in patients with type 1 diabetes are an ongoing area of research. The predictive low glucose management (PLGM) system incorporates continuous glucose sensor data into an algorithm and suspends basal insulin before the occurrence of hypoglycaemia. The system was evaluated in in-clinic studies, and has informed the parameters of a larger home trial to study its efficacy and safety in real life. Methods and analysis: The aim of this report is to describe the study design and outcome measures for the trial. This is a 6-month, multicentre, randomised controlled home trial to test the PLGM system in children and adolescents with type 1 diabetes. The system is available in the Medtronic MiniMed 640G pump as the 'Suspend before low' feature. Following a run-in period, participants are randomised to either the control arm with SAPT alone or the intervention arm with SAPT and Suspend before low. The primary aim of this study is to evaluate the time spent hypoglycaemic (sensor glucose
Original languageEnglish
Article number011589
Number of pages7
JournalBMJ Open
Volume6
Issue number4
DOIs
Publication statusPublished - 2016

Fingerprint Dive into the research topics of 'Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: Protocol for randomised controlled home trial to evaluate the Suspend before low function'. Together they form a unique fingerprint.

Cite this